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Introduction 
Cervical carcinoma still represents a significant public health 
problem. Around 11,069 cases of invasive cervical cancer were 
diagnosed in the United States in 2008 and 3869 women died from the 
disease. Worldwide, cervical cancer has an even greater impact, with 
nearly 529,828 new cases and 275,128 deaths reported annually [1] .
Patients with early stage cervical cancer treated with surgery 
or radiotherapy are likely to have a good prognosis [2]. However, 
substantial treatment failure still occurs and about 30% of the patients 
treated for cervical carcinoma develop progressive or recurrent 
tumors. Patients who suffer recurrence have a dismal prognosis with a 
1-year survival rate of between 15 and 20% [2].
Recurrent cervical cancer is defined as local tumor re-growth 
or the development of nodal or distant metastases at least 6 months 
after the lesion has regressed. Residual disease is that which is evident 
within 6 months of primary treatment. The average rate of recurrence 
is that approximately two-thirds of cases recur within the first 2 years 
following initial treatment, and 90% of cases recur by 5 years [3]. 
The risk of treatment failure depends on the initial staging and, 
consequently, on the chosen therapeutics. Risk factors for recurrence 
of cervical carcinoma include the histological type, size, depth of 
stromal invasion, and the nodal status at presentation. 
Pelvic recurrence can locate centrally or laterally in the pelvis. 
Extra-pelvic recurrence most commonly involves para-aortic lymph 
nodes, lungs, liver and bone [4].
Imaging Surveillance 
The early detection of recurrent disease in the pelvis may pose 
a diagnostic challenge, because symptoms are nonspecific, physical 
examination of the irradiated pelvis is often limited and cytological 
examination of the irradiated cervix has a poor sensitivity [5]. For 
these reasons and given that the therapeutic options for recurrence 
of cervical carcinoma depend on the location and extent of the 
recurrence, imaging can be crucial for early diagnosis and adequate 
management [4].
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There are no formal recommendations based on a good level 
of evidence for the follow up of the patients treated for cervical 
carcinoma [6].
Mabuchi et al. showed that routine physical history, physical 
examination, and CT scans were the most common first abnormal 
ttests leading to 86% of the recurrent disease diagnosis [7]. CT is 
an effective diagnostic tool for detection of recurrent tumor [8], 
however has little use in differentiating recurrent tumor from post-
therapeutic changes [9]. There is no consensus in the reviewed 
literature regarding the indication of pelvic MR for the follow-up of 
patients with medically treated cervical carcinoma and MR is usually 
performed when there is a clinical suspicion of recurrence. After 
surgery there is also no consensus for a systematic MR follow up with 
an exception for trachelectomy. Patients submitted to trachelectomy 
should be evaluated by MR at 6 months and 1 year given the higher 
recurrence rate comparing to patients who undergo brachytherapy or 
chemotherapy [10].
Normal Post-Therapeutical Imaging Findings 
Imaging evaluation of the treated cervical carcinoma depends on 
the knowledge of the normal post-therapeutical aspects after surgery 
and chemo-radiation therapy. Usually follow up MR is not indicated 
during the first 6 months after completion of radiation therapy due 
to limitations of MR in differentiating recurrent tumor from post-
operative and post-radiation changes [9].
The commonest surgical procedure is the Wertheim-Meigs 
surgery that comprises radical hysterectomy with resection of the 
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upper third of the vagina, excision of parametrial and paravaginal 
tissue, including the sacro-uterine ligaments, and dissection of pelvic 
and para-aortic lymph nodes.
The vaginal fornix is represented, both on CT and MR, by a 
soft-tissue linear structure [11] (Figure 1). MR has the advantages 
of multiplanar evaluation of the fornix and better definition of the 
vaginal wall. Normal vaginal vault has a strongly hypointense 
muscular wall in T2WI, with well-defined and regular contour. 
Frequently there is fibrotic scar tissue whose T2WI signal is slightly 
higher than the normal muscular tissue.
Laparoscopic vaginal radical trachelectomy is a fertility-
preserving alternative to radical hysterectomy or chemoradiation 
in young women with stage IA2 to IB1 cervical cancers [12]. The 
technique involves a proximal vaginotomy, cervical resection, and 
paracervical and paravaginal dissection. The cervix is resected, with 
preservation of the corpus uteri and an end-to-end anastomosis 
with the remaining vagina. Bilateral pelvic lymphadenectomy is also 
performed [13]. 
The imaging findings of the uterus after trachelectomy include 
the end-to-end anastomosis of the uterine corpus to the vaginal vault 
(Figure 2), frequently with a posterior neofornix that can present with 
nodular configuration. These MR features should be known to avoid 
false positive diagnosis of recurrent tumor. 
The para-vaginal dissection may cause vaginal wall thickening 
that is more prominent in the first 6 months and slowly diminishes 
till 1 year. Sometimes there is also loss of the low signal intensity 
on T2WI and this diffuse thickening can be mistaken for recurrent 
disease infiltrating the vaginal wall [13].
In the evaluation of patients submitted to radiation therapy MR 
is more effective than CT [8]. In postmenopausal patients, radiation 
therapy does not result in any significant changes of the uterus at MR 
imaging. In premenopausal patients the junctional zone and outer 
myometrium become indistinct and, after 6 months, the endometrium 
becomes thin and hypointense [14].
Tumors treated with RT respond with a decrease in size and signal 
intensity on MR imaging (Figure 3). The response may be immediate 
(3-6 months) or, in larger tumors, delayed (6-9 months) [15]. Hricak et 
al. reviewed the MR images of 69 patients submitted to radiotherapy 
to cervical cancer and reported that the reconstitution of the normal 
zonal anatomy of the cervix and homogeneous cervical low signal 
have high negative predictive value (97%) for recurrence [14]. An 
early (2–3 months) and significant decrease in the signal intensity and 
volume of the tumor indicates a positive response to radiation therapy 
and a high probability of complete remission [16]. 
Tumor Recurrence
The accuracy of MR for the diagnosis of recurrence after 
radiotherapy depends on the elapsed time since the ending of the 
therapeutics. In the first 6 months necrosis, inflammation and edema 
contribute to the higher signal intensity on T2WI making differential 
diagnosis with tumoral disease harder [17].
It is consensual that dynamic contrast-enhanced subtraction MR 
imaging for the differentiation of benign from malignant lesions is 
advisable for recurrence detection.
Diffusion-weighted MR also gives a valuable contribute for the 
evaluation of the irradiated cervix [18]. Hyperintense signal on high 
b-value images associated with lower ADC values are suggestive of 
recurrent tumor. 
Multiple studies found significant increases in lesion ADC 
values in patients treated with combined chemo-radiation therapy, 
however the post-therapeutical values might be inferior to normal 
cervical tissue (due to the presence of edema, hyaline degeneration 
and granulation tissue). Chen et al. found that the difference of ADC 
values between normal cervical tissue and cervical area after therapy 
was statistically significant (P < 0.01) and reported that the optimal 
ADC threshold values for distinguishing between cervical area 
before and after therapy is 1.255×10-3 mm2/s (sensitivity of 95.5% and 
specificity of 100%) and between normal cervical tissue and cervical 
area after therapy is 1.525×10-3 mm2/s (sensitivity and specificity of 
70% and 81.8%, respectively) [19]. 
Weber et al. found that the most helpful finding for differentiating 
recurrent cervical tumor from radiation fibrosis was the presence of 
 
Figure 1: Sagittal (a) and axial T2WI (b): the vaginal vault is visualized as a 
linear soft tissue structure.
 
Figure 2: Twenty six year old woman with FIGO IB1 cervical cancer, submitted 
to trachelectomy. Two years later sagittal T2WI (a and b) depict the utero-
vaginal anastomosis and the regularity and low signal intensity of the vaginal 
wall, better characterized after distension with ultrasound gel (b). 
 
Figure 3: First MR evaluation after finishing chemoradiation, Sagittal (a) and 
axial (b) T2WI show a small cervix with homogeneous low signal intensity. In 
DWI (c) and ADC map (d) there aren’t any signs of diffusion restriction that 
could be assigned to recurrence. Note the sacro-uterine ligaments thickening 
and prominence of peri-rectal adipose tissue, consequent to radiation.
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a soft-tissue mass with higher signal intensity than that of adjacent 
pelvic sidewall muscle on T2WI [20] and Hricak et al. documented 
that these findings carry a recurrence probability of 86% [14]. However 
the recurrent tumor may show diffuse growth making differential 
with post-therapeutics scar more difficult [9]. 
Recurrence exhibits an earlier and more pronounced enhancement 
compared with scar tissue, on condition that MR is not performed 
earlier than 6 months after the end of therapy [9]. 
Findings like widened endocervical canal and cervical diffuse 
high signal intensity are nonspecific and MR might not be conclusive 
(Figure 4).
The parametrium soft tissues may also undergo fibrotic changes 
and appear hypointense. This post-radiation imaging appearance may 
mimic parametrial invasion [21] thus becoming indistinguishable 
from the tumor. The intravenous administration of contrast material 
and DWI images can also help distinguishing between radiation-
induced parametrial fibrosis and residual or recurrent disease [19]. 
When morphological and functional MR evaluation is 
inconclusive biopsies may be warranted (Figure 5). Roy et al. [22] 
showed transrectal ultrasound guided biopsy to be a feasible, safe 
and accurate method for establishing a histopathological diagnosis of 
recurrence and CT guided biopsy of lymph nodes and metastases is a 
current procedure (Figure 6). 
In addition, serial or follow-up MR imaging is useful for 
distinguishing recurrent disease from radiation-induced fibrosis, as 
the latter is expected to remain stable or diminish over time [8]. 
Most cervical tumors are 18F-fluorodeoxyglucose (FDG) avid, 
with exception to adenocarcinomas, which may reveal low FDG 
uptake. Revision of studies using FDG-PET/CT in the evaluation of 
recurrence/metastases in patients with uterine cancer revealed high 
diagnostic accuracy with 90-93% sensitivity, 81-100% specificity and 
87-96% accuracy [23]. It is especially useful for the assessment of 
peritoneal dissemination, lymph node metastases, local recurrence, 
and bone/muscle metastases and may have the greatest utility in 
situations in which tumor marker levels are rising and conventional 
imaging studies show negative or equivocal findings [3,23]. 
Central Tumor Recurrence 
About 30-45% of recurrences after radical hysterectomy are 
central-pelvic-type, generally situated above the vaginal cuff, 
between the bladder and the rectum (Figure 7). Five-year survival 
rates reported by literature for these central recurrences vary from 
6% to 77% . Patients with a central recurrence seem to have a better 
prognosis compared to those with recurrence of the pelvic wall [24].
Central recurrence can affect the cervix, vagina, parametria and 
ovaries and grow to involve the bladder, rectum, or side wall. After 
radical hysterectomy most tumors show supra-vaginal recurrence 
(20%) at the vaginal stump (Figure 8) and at the recto-vaginal space 
[9]. Skip lesions in the vagina may be seen in recurrent cervical cancer, 
in which case lesions may be seen in the distal vagina (Figure 9). 
Patterns of involvement of the vagina follow the growth pattern of the 
primary cervical cancer (eg, as a mass- like lesion or as an infiltration 
along the vaginal wall) [25].
  
Figure 4: First MR evaluation after finishing chemoradiation. Sagittal (a) 
and axial T2WI (b) reveal a small cervix, predominantly hypointense. A slight 
central hyperintensity is noticed but attributed to inflammatory effects of 
radiation. These findings were stable in subsequent evaluations. 
 
Figure 5: Uterine cervical carcinoma FIGO IIB that finished chemoradiation 
4 months before. In the sagittal (a) and axial (b) T2WI a central area of high 
signal intensity is identified in the cervix (arrow). This area could be related 
to post-radiation inflammatory effects (note the prominence of peri-rectal 
adipose tissue and low signal intensity striation of the parametria). Although 
it presents slight high signal intensity in b-1000 DWI (c) and signs of water 
restriction in the ADC map (d) (dashed arrows). Biopsies confirmed tumoral 
recurrence.
 
Figure 6: Cervical cancer FIGO IIIB submitted do chemoradiation. Twelve 
months after finishing therapy surveillance CT (a, b - axial contrast enhanced 
CT) revealed para-aortic lymph node enlargement (a) and a solid nodule in 
the vaginal vault (arrow in b). The vaginal vault nodule was biopsied under 
trans-rectal ultrasound guidance (c) and the para-aortic lymph node submitted 
to CT-guided biopsy (d). Both revealed neoplastic squamous cells according 
to central and lymph node recurrence.
 
Figure 7: Uterine cervical tumor FIGO IIB (a-sagittal T2 WI) treated with 
chemoradiation. A year after finishing therapy MR (b and c-sagittal and axial 
T2WI) show central cervical recurrence without signs of parametrial invasion.
 
Figure 8: Vaginal vault recurrence. Axial (a) and sagittal (b) T2WI images 
show a small low signal intensity solid tumor in the vaginal vault (arrow). 
This lesion is high signal intensity on DWI with b-1000 (c) and has low signal 
intensity on the ADC map (d).
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Kim et al. reported a higher incidence of central recurrence among 
patients treated by radiation therapy than by surgery [26].
The most common CT and MR imaging feature of recurrent 
tumor of the primary site is an irregular mass averaging 4-7 cm in 
diameter between the bladder and rectum [26]. Recurrent tumor 
may be recognized on CT scans obtained with intravenous contrast 
material, on which it may appear as a soft-tissue mass with diminished 
enhancement compared with that of normal cervical tissue [8]. On 
MR recurrence has high signal intensity on T2WI, similar to the 
corresponding primary tumor [8] (Figure 10). 
Hydrometra, depicted by CT and MR as a symmetrically enlarged 
uterine corpus containing non-enhanced fluid [9], can be associated 
with central recurrence due to the obstruction of the internal os by 
the tumor. However it can also be due to radiogenic fibrosis and its 
appreciation depends on the definition of a tumoral mass (Figure 11). 
Central pelvic recurrence with anterior extension may lead to 
ureteral obstruction by direct encasement of the ureter or by tumor 
infiltration of the bladder wall, which results in obstruction at the 
ureteral orifice [9].
Although the loss of the adipose cleavage plan of the tumoral 
mass with bladder and rectum rise the suspicion of visceral invasion 
the imaging diagnosis depends on the identification of luminal 
tumoral mass. The MR imaging findings of bladder invasion include 
nodularity and irregularity of the bladder wall, masses protruding 
into the bladder lumen, high signal intensity of the anterior aspect 
of the posterior bladder wall, and abnormal soft-tissue strands in the 
utero-vesical space [27]. Invasion of the rectum usually occurs at the 
recto-sigmoid junction and is detected by mass effect, spiculation, and 
luminal narrowing (Figure 12) [28]. 
Pelvic Side Wall Recurrence
Pelvic side wall recurrence is characterized either by direct 
invasion of the mass to the pelvic side-wall by means of a linear strand 
of soft tissue and involving loss of the fat planes, or by confluence of 
the solid mass and the muscle of the pelvic wall [27]. At times pelvic 
recurrences are identified as pelvic side wall masses that are not 
associated with a centrally located pelvic mass [28]. 
Recurrent tumor of the pelvic sidewall may manifest with pain due 
to nerve infiltration or leg edema due to obliteration of the lymphatics [9]. 
The imaging criteria are the same used for the initial staging: 
the distance tumor–side wall is less than 3 mm; the piriformis and 
obturator internus muscles can be enlarged and demonstrate an 
enhancing soft-tissue mass; the iliac vessels can be encased and 
narrowed by tumor; direct extension and destruction of the pelvic 
bones may occur. 
Kim et al. reported that there is no significant difference in the 
incidence of pelvic side-wall extension between patients who undergo 
surgery and those treated by radiation therapy [26].
Lymph Node Recurrence
In uterine cervical carcinoma lymphatic involvement has 
traditionally been separated into primary and secondary nodal 
groups. The first of these consists of the paracervical, parametrial, 
internal and external iliac, and obturator nodes, while those comprised 
by the second include the sacral, common iliac, inguinal and para-
aortic [29]. In general, paracervical and parametrial lymph nodes 
are involved first, followed by the obturator nodes, the remaining 
external iliac nodes, and the internal iliac nodes. Extra-pelvic lymph 
nodes, including the supra-clavicular, para-aortic (Figure 13), and 
 
Figure 9: Distal vaginal recurrence. Patient submitted to chemoradiation for 
cervical carcinoma. Nodularity of distal vagina was noticed. Sagittal (a) and 
axial (b) T2WI reveal parietal thickening of the  lower third of the vagina with 
high signal intensity on the T2WI. Recurrence of the cervical carcinoma was 
confirmed by vaginal biopsy. The cervix had the usual post-therapy aspects 
(small, diffuse low signal intensity) and no signs of cervical recurrence were 
identified.
 
Figure 10: Cervical uterine carcinoma FIGO IIA1 treated with chemoradiation. 
Sagittal T2WI shows the primary tumor (a) with high signal intensity suggestive 
of hyper-cellularity. Fourteen months later sagittal T2WI (b) reveals cervical 
recurrence and patient was submitted to hysterectomy. Sixteen months later 
(c-sagittal and d-axial T2WI) pelvic RM depicts a vaginal vault recurrence with 
the same signal characteristics of the initial tumor. 
 
Figure 11: About 2 years after chemoradiation for cervical cancer, surveillance 
CT found hydrometra and MR was made for better characterization. Sagittal 
T2WI (a) depicts a high cervical recurrence causing obstruction of the cervix, 
with hydrometra. Axial T2WI (b and c) reveal recurrent tumor in the cervix 
with obstructing the internal os and hydrometra. The tumor doesn’t invade 
the parametria but the left parametrium is strongly hypointense (arrow in b) 
and there is left ureteral dilatation (arrowhead in c). These findings, as also 
the rectum and sigmoidal parietal thickening, were assigned to inflammatory 
effects of radiation.
 
Figure 12: Central recurrence of uterine cervical carcinoma after hysterectomy 
for uterine cervical carcinoma FIGO IB1. Sagittal (a) and axial (b) T2WI show 
a large tumor that invades the bladder (thin arrow) and rectum lumen (thick 
arrow). There is also loss of cleavage plan and invasion of the pelvic wall 
muscles. Note a metastasis in the anterior abdominal wall (*).
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inguinal, are common sites of distant metastases. The prevalence of 
recurrence at extra-pelvic lymph nodes is higher in patients treated 
with radiation therapy than in those who undergo surgery; this 
is probably because this tumor stage is generally more advanced. 
Multiple extra-pelvic and extra-abdominal nodal sites of recurrence, 
including the para-bronchial, supra-clavicular, and axillary nodes, 
have been reported but are less frequently involved than the primary 
and secondary groups [8]. 
Yang et al. compared the results of CT, MR and pathological 
evaluation of 949 lymph nodes in 43 women with biopsy proven cervical 
cancer and concluded that helical CT and MRI imaging showed similar 
accuracy in lymph node evaluation (89.5% and 85.5%, respectively) [18]. 
The findings of nodal metastases range from scattered, minimally 
enlarged lymph nodes to large, conglomerate nodal masses at CT and 
MR imaging [8]. Although enlarged lymph nodes may be hyperplastic 
and lymph nodes smaller than 1 cm may contain metastatic disease, 
nodes with a transverse diameter greater than 10 mm are usually 
considered malignant. Central necrosis within a lymph node is a 
strong predictor of metastatic disease (positive predictive value of 
100%) [18,30]. Recent studies showed the potential of DW imaging 
to differentiate benign from malignant pelvic lymph nodes based on 
their underlying mean ADC value [31].
Distant Recurrent Disease 
After the pelvis and lymph nodes, the solid organs of the abdomen 
are the most frequent sites of involvement of recurrent cervical 
carcinoma [28]. 
Liver metastases are present in one-third of patients and appear 
as solid masses with variable enhancement. Adrenal metastases 
are usually from cervical adenocarcinomas and are present in 
approximately 15% of patients. Peritoneal metastases appear as 
soft-tissue masses and ascites and are present in 5%–27% of cases in 
autopsy series (Figure 14) [15,28]. 
Imachi et al. documented pulmonary metastases in 6% of 817 
patients with uterine cervical carcinoma and 81% of those had local 
recurrence or other distant metastatic lesions [29]. Lymphangitic 
carcinomatosis is seen in less than 5% of patients and appears as 
diffuse interstitial lung disease [25]. Mediastinal or hilar adenopathy 
and pleural lesions or effusions are present in approximately one-
third of patients with metastatic disease to the chest [15]. 
The prevalence of osseous metastases (Figure 15) in the setting 
of recurrent cervical carcinoma ranges from 15% to 29%. The 
vertebral bodies are the most frequently involved bones, followed 
by the pelvis, ribs, and extremities. The most common mechanism 
of bone involvement is by direct extension of neoplasm from para-
aortic nodes into the adjacent vertebral bodies (Figure 13). It can also 
occur by lymphatic or hematogenous spread or from direct extension 
of pelvic recurrence. Bone metastases may appear as destructive 
lesions associated with soft-tissue masses of variable size. The absence 
of a soft tissue mass, slow progression, blastic elements, and sharply 
defined borders on CT suggest radiation necrosis [30]. In some lesions 
gadolinium-enhanced fat-suppressed T1WI is useful for the diagnosis 
by the definition of foci of enhancement within the marrow space [28]. 
Conclusion
Uterine cervical cancer recurrence is common (about two thirds 
within the first 2 years) and carries a dismal prognosis. 
CT and MRI play key roles in identifying recurrent disease. 
Although both have reasonable sensitivities [3] it is generally 
accepted that MR is superior in distinction between tumor and 
post-radiotherapy inflammatory and fibrotic changes. Dynamic 
contrast-enhanced subtraction and diffusion weighted MR imaging 
are advisable. PET/CT has been considered a highly accurate imaging 
technique for restaging [23].
Knowledge of the wide spectrum of imaging findings after 
surgery and radiotherapy is crucial for evaluation after cervical 
cancer therapy. Reconstitution of the normal zonal anatomy of the 
cervix and homogeneous cervical low signal have high negative 
predictive value (97%) for recurrence. The most specific sign of central 
recurrence is a hyperintense soft-tissue mass (T2WI) with earlier and 
pronounced enhancement. Imaging criteria of pelvic wall recurrence 
are the same used for the initial staging (distance tumor–side wall is 
less than 3 mm). Published studies show a certain degree of overlap 
between benign and malignant pelvic lymph nodes, similar accuracy 
for CT and MR and have not been able to define the negative predictive 
value of DW imaging [31]. Lung, bone and liver are the most common 
locations of distance recurrence [32].
 
Figure 13: Lymph node recurrence. Non-enhanced CT depicting left para-
aortic lymph node conglomerate with invasion of the psoas muscle and 
erosion of the adjacent vertebral body. 
 
Figure 14: Uterine cervical cancer FIGO IIB treated with chemoradiation. 
Surveillance CT (axial non-enhanced CT) reveals hydrometra (a), ascites (a) 
and peritoneal (b) and pulmonary (c) metastases.
 
Figure 15: Uterine cervical carcinoma. Sagittal T2WI (a) shows the primary 
tumor which was a FIGO IIIB. Six months after finishing chemoradiation a 
pathological humeral fracture was diagnosed (b-humeral X-ray) and CT (c) 
and biopsy confirmed cervical carcinoma metastasis. 
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